Cyclosporin treatment of glomerular diseases

Bibliography

• VON GRAFFENREID B, FRIEND D, SHAND N, SCHEISS W,TIMONEN P: Cyclosporin A (Sandimmun®) in autoim-mune disorders. In: Cyclosporin. Mode of action and clinical application. AW Thomson (Ed.), Kluwer Academic Publisher, Dordrecht (1989):213–251.
   Google Scholar
• AMBALAVANAN S, FAUVEL JP, SIBLEY RK, MYERS BD:Mechanism of the antiproteinuric effect of cyclosporin in membranous nephropathy. J. Am. Soc. Nephrol. (1996) 7:290–298.
   PubMed Web of Science ®Google Scholar
• •This study examined the effects of cyclosporin on GFR and proteinuria in patients with nephrotic syndrome and MN. A sub-group provided interesting insights into the mechanism of cyclosporin's antiproteinuric effects.
   Google Scholar
• WIEGMANN TB, SHARMA R, DIEDRICH DA, SAVIN VJ: Invitro effects of cyclosporin on glomerular function. Am. J. Merl. ScL (1990) 299(3):149–152.
   PubMed Web of Science ®Google Scholar
• SAVIN, VJ: Mechanisms of proteinuria in noninflam-matory glomerular diseases. Am. J. Kidney Dis. (1993) 21:347–362.
   PubMed Web of Science ®Google Scholar
• TEJANI AT, BUTT K, TRACHTMAN H, SUTHANTHIRAN M,ROSENTHAL CJ, KHAWAR MR: cyclosporin A induced remission of relapsing nephrotic syndrome in children. Kidney Int. (1988) 33:729–734.
   PubMed Web of Science ®Google Scholar
• •This was a short-term trial of cyclosporin in steroid-resistant and steroid-dependent patients with nephrotic syndrome. The authors measured both T3 cell and IL-2 levels in an attempt to correlate them with responsiveness to cyclosporin.
   Google Scholar
• TEJANI A, SUTHANTHIRAN M, POMRANTZ A: A random-ized controlled trial of low-dose prednisone and cyclosporin versus high-dose prednisone in nephrotic syndrome of children. Nephron (1991) 59:96–99.
   PubMed Web of Science ®Google Scholar
• CATTRAN D, GREENWOOD C, BERNSTEIN K et al.:Results of a 6 month randomized controlled trial of cyclosporin (T) vs. placebo (c) in adults with steroid resisitant idiopathic focal segmental glomeruloscle-rosis (SR-FSGS). J. Am. Soc. Nephrol. (1995) :415–415.
   Google Scholar
• CAPODICASA G, DE SANTO NG, NUZZI F: Cyclosporine A in nephrotic syndrome of childhood- A 14 month experience. Int. J. Pediatr. Nephrol. (1986) 7:69–72.
   PubMedGoogle Scholar
• GARIN EH, ORAK JK, HIOTT KL: Cyclosporine therapy for steroid-resistant nephrotic syndrome. Am. J. Dis. Child (1988) 142:985–988.
   PubMedGoogle Scholar
• GARCIA C, MICHELON T, BARROS V et al.: Cyclosporinein the treatment of steroid-dependent and steroid-resistant idiopathic nephrotic syndrome in children. Transplant Proc. (1998) 30:4156–4157.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, RIZZONI G, EDEFONTI A etal.: A random-ized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. (1993) 43:1377–1384.
   Google Scholar
• NIAUDET P: Comparison of cyclosporin and chloram-bucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr. Nephrol. (1992) 6:1–3.
   PubMed Web of Science ®Google Scholar
• NIAUDET P: Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. j Pediatr. (1994) 125:981–986.
   Google Scholar
• SINGH A, TEJANI C, TEJANI A: One-center experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr. Nephrol. (1999) 13:26–32.
   PubMed Web of Science ®Google Scholar
• INGULLI E, TEJANI A: Severe hypercholesterolemia inhibits cyclosporine A efficacy in a dose-dependant manner in children with nephrotic syndrome. J. Am. Soc. Nephr. (1992) 3:254–259.
   PubMed Web of Science ®Google Scholar
• MEYRIER A, NOEL L-H, AURICHE P, CALLARD P:Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int. (1994) 45:1446–1456.
   PubMed Web of Science ®Google Scholar
• •This study employed pre- and post-treatment renal biopsies to document the progression of disease and toxic effects of treatment in nephrotic patients treated with cyclosporin.
   Google Scholar
• PONTICELLI C, PASSERINI P: Treatment of the nephrotic syndrome associated with primary glomeru-lonephritis. Kidney Int. (1994) 46:595–604.
   PubMed Web of Science ®Google Scholar
• KORBET SM, SCHWARTZ MM, LEWIS EJ: Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am. J. Kidney Dis. (1994) 23:773–783.
   PubMed Web of Science ®Google Scholar
• CATTRAN D, GREENWOOD C, HEBERT L et al. Follow up results from a randomized controlled trial (RCI) of cyclosporine (1) vs. placebo (C) in adults with steroid resistant idiopathic focal segmental glomeruloscle-rosis (SR-FSGS). J. Am. Soc. Nephrol. (1995):414–414 (Abstract)
   Google Scholar
• CATTRAN DC, APPEL GB, HEBERT LA et al.: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. (1999) 56:2220–2226.
   Google Scholar
• LIEBERMAN KV, TEJANI A: A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomeruloscle-rosis in children. J. Am. Soc. Nephrol. (1996) 7:56–63.
   PubMed Web of Science ®Google Scholar
• MEYRIER A, CONDAMIN MC, BRONEER D FOR THE COLLABORATIVE GROUP OF THE FRENCH SOCIETY OF NEPHROLOGY: Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: Minimal-change disease and focal-segmental glomeruloscle-rosis. Gun. Nephrol. (1991) 35 (Suppl. 0:37–42.
   Google Scholar
• NIAUDET P, BROYER M, HABIB R: Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin. Nephrol. (1991) 35 (Suppl. 0:531–536.
   Google Scholar
• PONTICELLI C, ZUCCHELLI P: A 10-year follow-up of arandomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. (1995) 48:1600–1604.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, ZUCHELLI P, IMBASCIATI E et al.: Controlled trial of methylprednisolone and chloram-bucil in idiopathic membranous nephropathy. N Eng. J. Med. (1984) 310:946–950.
   PubMed Web of Science ®Google Scholar
• SCHIEPATTI MD, MOSCONI L, PERNA A et al.: Prognosis of untreated patients with idiopathic membranous nephropathy. N Eng. J. Med. (1993) 329:85–89.
   PubMed Web of Science ®Google Scholar
• HOGAN SL, MULLER KE, JENNETTE JC, FALK RJ: A review of therapeutic studies of idiopathic membranous glomerulopathy. Am. J. Kidney Dis. (1995) 25:862–875.
   PubMed Web of Science ®Google Scholar
• IMPERIALE TF, GOLDFARB S, BERNS JS: Are cytotoxic agents beneficial in idiopathic membranous nephro-pathy? A meta-analysis of the controlled trials. J. Am. Soc. Nephr. (1995) 5:1543–1545.
   PubMed Web of Science ®Google Scholar
• DESANTO NG, CAPODICASA G, GIORDANO C: Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chloram-bucil with cyclosporine. Am. J. Nephrol. (1989) 7:74–76.
   Web of Science ®Google Scholar
• ROSTOKER G, MAADI AB, SANDREUX T: Long term cyclosporin A therapy for severe idiopathic membra-nous nephropathy. Nephron (1997) 63:335–341.
   Web of Science ®Google Scholar
• GUASCH A, SURANYI M, NEWTON L, HALL BM, MYERSBD: Short-term responsiveness of membranous glomerulopathy to cyclosporine. Am. J. Kidney Dis. (1992) 20:472–481.
   PubMed Web of Science ®Google Scholar
• CATTRAN, DC, GREENWOOD, C, RITCHIE, S et al.: A controlled trial of cyclosporin in patients with progressive membranous nephropathy. Kidney. Int. (1995) 47:1130–1135.
   PubMed Web of Science ®Google Scholar
• •This was a landmark study which demonstrated the benefi-cial effects of cyclosporin in slowing the progression of membranous nephropathy.
   Google Scholar
• D'AMICO G: The commonest glomerulonephritis in the world: IgA nephropathy. Quart. J. Med. (1987) 64:709–727.
   Google Scholar
• BERG UB: Long term follow up of renal function in IgAnephropathy. Arch. Dis. Child. (1991) 66:588–592.
   PubMed Web of Science ®Google Scholar
• DECAESTECKER MP, BOTTOMLEY M, TELFER BA: Detection of abnormal peripheral blood mononuclear cell cytokine networks in human IgA nephropathy. Kidney Int. (1993) 44:1298–1308.
   PubMed Web of Science ®Google Scholar
• SCHENA FP, GESUALDO L, MONTINARO V: Immunopa-thological aspects of immunoglobulin A nephropathy and other mesangial proliferative glomerulonephri-tides. J. Am. Soc. Nephrol. (1992) 2:167–182.
   Web of Science ®Google Scholar
• DONADIO JV: Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin. Proc. (1991) 66:1018.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI Y, FUJII K, HIKI Y et al: Steroid therapy in IgA nephropathy: A prospective pilot study in moderate proteinuric cases. Quart. J. Med. (1986) 61:935–943.
   PubMedGoogle Scholar
• POZZI C, BOLASCO PG, FOGAZZI GB et al.: Corticoster-oids in IgA nephropathy: a randomised controlled trial. Lancet (1999) 353:883–887.
   PubMed Web of Science ®Google Scholar
• BENNETT WM, WALKER RG, KINCAID-SMITH PS: Treatment of IgA nephropathy with eicosapentanoic acid(EPA): a two-year prospective trial. Clin. Nephrol. (1989) 31:128–131.
   PubMed Web of Science ®Google Scholar
• LAI KN, LAI M-M, VALLANCE-OWN J: A short-termcontrolled trial of cyclosporin-A in IgA nephropathy. Transplant Proc. (1988) 20:297–303.
   PubMed Web of Science ®Google Scholar
• ERBAY B, KARATAN O, DUMAN N, ERTUG AE: The effectof cyclosporin in idiopathic nephrotic syndrome resistant to immunosuppresive therapy. Transplant Proc. (1988) 20(3 Suppl. 4):289–292.
   Google Scholar
• VALERI A, RADHAKRISHNAN J, ESTES D et al.: Intrave-nous cyclophosphamide treatment of severe lupus nephritis: a prospective five year study. Clin. Nephrol. (1994) 42:71–78.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, AUSTIN HAI, VAUGHN EM et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 340:741–745.
   PubMed Web of Science ®Google Scholar
• BANSAL VK, BETO JA: Treatment of lupus nephritis: ameta-analyses of clincal trials. Am. J. Kidney Dis. (1997) 29:193–199.
   PubMed Web of Science ®Google Scholar
• ISRAEL-BIET D, NOEL LH, BACH MA, DARDENNE M, BACH JF: Marked reduction of DNA antibody produc-tion and glomerulopathy in thymulin (FTS-Zn) of cyclosporin A treated (NZB X NZW)Fi mice. Clin. Exp. Immunol. (1983) 54(2):359–365.
   PubMed Web of Science ®Google Scholar
• JONES MG, HARRIS, G: Prolongation of life in female(NZB/NZW)Fi hybrid mice by cyclosporin-A. Clin. Exp. Immunol. (1985) 59:1–9.
   PubMed Web of Science ®Google Scholar
• GUNN HC: Successful treatment of autoimmunity in(NZBxNZW)Fi mice with cyclosporin and (Nva2)-cyclosporin:I.Reduction of autoantibodies. Clin. Exp. Immunol. (1986) 64:225–233.
   PubMed Web of Science ®Google Scholar
• APPLEBY P, WEBBER DG, BOWEN JG: Murine chronicgraft-versus-host disease as a model of systemic lupus erythematosus: effect of immunosuppressive drugs on disease development. Clin. Exp. Immunol. (1989) 78:449–453.
   PubMed Web of Science ®Google Scholar
• MIESCHER PA, FAVRE H, MIHATSCH MJ, CHATELANAT F, HUANG YP, ZUBLER R: The place of cyclosporin A in the treatment of connective tissue diseases. Transplant. Proc. (1994) 20\(Suppl. 4):224–237.
   Google Scholar
• MIESCHER PA, MIESCHER A: Combined cyclosporin-steroid treatment of systemic-lupus erythematosus. In: Cyclosporin in autoimmune disease. R Schindler (Ed.), Springer-Verlag, Berlin (1985)334–334.
   Google Scholar
• FAVRE H, MIESCHER A, HUANG YP, CHATELANAT F, MIHATSCH MJ: Cyclosporin in the treatment of lupus nephritis. Am. J. Nephrol. (1989) 9(Suppl.):57–60.
   Google Scholar
• FEUTREN G, QUERIN S, NOEL LH et al.: Effects ofcyclosporin in severe systemic lupus erythematosus. Pediatr. (1987) 111:1063–1068.
   Web of Science ®Google Scholar
• TOKUDA M, KURATA N, MIZOGUCHI A et al: Effect of low-dose cyclosporin A on systemic lupus erythema-tosus disease activity. Arth. Rheum. (1994) 37:551–558.
   PubMed Web of Science ®Google Scholar
• ENRIQUEZ R, TOVAR JV, AMOROS F, CABUEZUELO JB, GONZALEZ C: Can cyclosporin be used without steroids in systemic lupus erythematosus? Nephron (1991) 57:367–368.
   PubMed Web of Science ®Google Scholar
• HUSSEIN MM, MOOIJ JM, ROUJOULEH H: Cyclosporin in the treatment of lupus nephritis including two patients treated during pregnancy. Clin. Nephrol. (1993) 40:160–163.
   PubMed Web of Science ®Google Scholar
• LEFRANCOIS N, DETEIX P, LAVILLE M, ZECH P:Treatment of systemic lupus with cyclosporin A: a patient with a 1-year follow-up. Kidney Int. (1984) 26:225
   Web of Science ®Google Scholar
• FAVRE H, MIESCHER PA, LEMOINE R: Use of cyclosporinin the treatment of autoimmune disorders. Transplant Proc. (1994) 26:3194–3196.
   PubMed Web of Science ®Google Scholar
• RADHAKRISHNAN J, SZABOLCS M, D'AGATI V, NICOLAIDES M, WHARTON R, APPEL GB: Lupus membranous nephropathy(LMN):Course and prognosis in 50 patients. J. Am. Soc. Nephr. (1993):284 (Abstract).
   Google Scholar
• BALDWIN DS, GLUCK MC, LOWENSTEIN J, GALLO GR:Lupus nephritis: Clinical course as related to morphol-ogic forms and their transitions. Am. J. Med. (1977) 62:12–30.
   PubMed Web of Science ®Google Scholar
• APPEL GB, COHEN DJ, PIRANI CL, MELTZER JI, ESTES D: Long-Term follow-up of patients with lupus nephritis. Am. J. Med. (1987) 83:877–885.
   PubMed Web of Science ®Google Scholar
• DONADIO JVJR: Treatment of membranous nephro-pathy in systemic lupus erythematosus. Nephrol. Dial. Transplant (1992) 7 (Suppl. 1):97–104.
   Google Scholar
• APPEL GB, SILVA FG, PIRANI CL, MELTZER JI, ESTES D: Renal involvement in systemic lupus erythema-t osus (SLE):A study of 56 patients emphasizing histologic classification. Medicine (1978) 57 (5):371–410.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, RIVOLTA E: cyclosporin in nephrotic syndrome. Transplant Proc. (1988) 20:253–258.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, LAN SP, ROHDE RD, LACHIN JM: A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collabo-rative Study Group. N Engl. J. Med. (1992) 326:425–427.
   PubMed Web of Science ®Google Scholar
• RADHAKRISHNAN J, KUNIS CL, D'AGATI V, APPEL GB: cyclosporin treatment of lupus membranous nephro-pathy. Gun. Nephrol (1994) 42:147–154.
   Google Scholar
• •This was the largest uncontrolled trial of cyclosporin in class V lupus at our institution.
   Google Scholar
• AUSTIN HA, VAUGHAN EM, BOUMPAS DT, KLIPPEL JH, BALOW JE: Lupus membranous nephropathy: controlled trial of prednisone, pulse cyclophospha-mide, and cyclosporine A. J. Am. Soc. Nephr. (1996):1328 (Abstract).
   Google Scholar
• SCHOLLMEYER P, GROTZ W: Ciclosporin in the treatment of Wegener's granulomatosis (WG) and related diseases. APMIS Suppl. (1990) 19:54–55.
   PubMedGoogle Scholar
• BORLEFFS JCC, DERKSEN RHVVM, HENE RJ: Wegener's granulomatosis and cyclosporin. Transplant Proc. (1988) 20\(Suppl. 4):344–345.
   Google Scholar
• HARLEY N, IHLE B: Wegener's granulomatosis - use ofcyclosporin-A: a case report. Aust. NZ J. Med. (1990) 20:71–73.
   PubMedGoogle Scholar
• HAUBITZ M, KOCH KM, BRUNKHORST R: Cyclosporin for the prevention of relapses in ANCA-associated vasculitis. Nephrol. Dial. Transplant. (1998) 13 (8):2074–2076.
   PubMed Web of Science ®Google Scholar
• HOYER PF: Complications of cyclosporin therapy. In: Cyclosporin in the Therapy of Renal Disease. A Tejani (Ed.), Karger, Basel (1995) :111–123.
   Google Scholar
• FEUTREN G, MIHATSCH MJ, FOR THE INTERNATIONAL KIDNEY BIOPSY REGISTRY OF CYCLOSPORIN IN AUTOIMMUNE DISEASE: Risk factors for cyclosporin nephropathy in patients with autoimmune diseases. N Engl. J. Med. (1992) 326:1654–1660.
   PubMed Web of Science ®Google Scholar